Specifically, chemo-ICIs as the first line of treatment were linked to a response rate of 46%, while ICI alone generated a response rate of 37%, indicating that chemo-immunotherapy may be the optimal management option for the advanced KRAS-mutant NSCLC patients both in white and Asian populations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.